fibrosis from the FBR, we first analyzed fibrotic capsule surrounding human breast implants and found increased numbers of interleukin (IL) 17 expression and fibrosis. Discovery of a feed-forward loop between the TH17 and senescence response to synthetic materials introduces new targets for therapeutic intervention in the foreign body response.
Main Text:
Synthetic biomaterials serve as the building blocks of medical devices and implants.
Biomaterials were historically selected based on their physical properties such as mechanical strength and durability while at the same time inciting minimal host response after implantation.
Despite that many advances that medical implants bring to medicine, synthetic materials suffer to varying extents from the foreign body response (FBR) that leads to a capsule of fibrous tissue surrounding the implant [1] . Manipulating chemistry and surface properties can mitigate the FBR to a degree, but even a minor response can lead to device failure over time which necessitates surgical removal. While fibrosis may be leveraged to stabilize some implants such as orthopedic implants or stents, it can also lead to implant contraction in the case of hernia meshes and breast implants. Silicone breast implants are widely used in medical practice but develop fibrotic capsules that can necessitate replacement [2] . Further, some recipients experience breast implant syndrome that includes increased risk of rheumatologic disorders [3] . Recent reports on lymphomas arising around synthetic breast implants designed with a surface to enhance fibrotic immobilization further validate the relevance of murine studies demonstrating the procarcinogenic potential of the FBR [4] [5] [6] .
The classic FBR to synthetic materials was first defined in the 1970s [7] [8] [9] . It is characterized by protein adsorption and complement activation followed by migration of proinflammatory innate immune system cells, in particular, neutrophils and macrophages.
Macrophages fuse to form foreign body giant cells and fibroblasts are activated to secrete extracellular matrix leading to formation of fibrous capsule. Macrophages and the innate immune response are considered central to the FBR and implant fibrosis, however, since the innate and adaptive immune systems are intimately connected, it is possible that the adaptive immune system is also contributing to the FBR [10] . Implantation of a biomaterial or clinical devices may therefore impact immune memory and systemic immune responses with yet unexplored clinical consequences.
T cells are a key component of the adaptive immune system that is increasingly recognized for their role in wound healing and tissue repair. CD4 + helper T cells regulate bone, liver, and muscle repair processes [11] [12] [13] . The TH2 T effector cells responding to proregenerative biological scaffolds secrete interleukin 4 (IL4) and direct the function of macrophages to promote muscle repair [13] . The presence of T cells has been recognized in the FBR in animal models and surrounding clinical implants but their nature, activation status and role in the response is still largely unknown [10, 14] . Adaptive responses that depend on T cells, which conventionally recognize MHC-presented peptide antigens, have not been seriously considered in the response to synthetic materials despite their increasing association with fibrotic disease [15] [16] [17] . Beyond T cells, the influence of other immune cell types such as gamma-delta (γδ) T cells and innate lymphoid cells (ILCs) in regulation of the biomaterials response, tissue damage, and fibrosis remains unexplored.
The connection between the immune response to biomaterials, fibrosis and senescent cells (SnCs) is also unexplored. SnCs are characterized by growth arrest but are far from quiescent. Accumulation of SnCs is associated with age-related chronic diseases but they also regulate development and wound healing [18, 19] . SnCs exert their effects through the secretion of a senescence associated secretory phenotype (SASP). The SASP includes many immunological cytokines that are being associated with specific immune phenotypes [20] .
Clearance of SnCs using knockout models and senolytic drugs reduces fibrosis in idiopathic pulmonary fibrosis (IPF) and reduces inflammation and disease symptoms in arthritis, diabetes, and cardiovascular disease [21] [22] [23] [24] . (pSTAT3) that is essential for IL17 expression ( Fig 1B, SFig 1D ) [27] . Overall, these results support a consistent type 17 immune response to human silicone implants independent of the surface properties and implantation site, with both γδ + and CD4 + T cells serving as the primary contributors to IL17 production.
To investigate if the TH17/IL17 immune signature contributed to the fibrosis observed in human tissue surrounding the implants (Fig. 1B) , we evaluated mRNA levels of collagen I and III, transforming growth factor β (Tgfβ), and the fibroblast specific protein S100a4 ( Fig 
Innate and adaptive lymphocytes sequentially contribute to chronic IL17 production in response to synthetic materials
To further investigate the role of IL17 in implant-associated fibrosis suggested by our clinical findings, and understand the mechanism linking the type 17 immune response to the FBR, we implanted synthetic materials in C57BL/6 mice. Materials were placed both subcutaneous or in a muscle wound to mimic surgical implantation and tissue trauma.
Poly(caprolactone), PCL, was used as the primary model synthetic material since it induces a robust inflammatory response and is also a component of clinical implants [31] . that can respond quickly to danger associated molecular pattern (DAMPs) and cytokines independently of TCR signaling, IL17-producing γδ + T cells (γδ T17) that can recognize nonpeptide antigens such as lipids, phosphoantigens and carbohydrates, and adaptive CD4 + T cells (TH17) that can be activated, specifically through the alpha beta TCR receptor (Fig 2A-D) [32] .
At 1-week post-implantation in the murine model, ILCs and γδ + T cells were the primary source of IL17 (Fig 2B) . CD4 + T cells exhibited no significant differences between IFNγ, IL4 or IL17 expression at one week by intracellular staining (Fig 2A, 2B (Fig 2E) . PCL implanted into the subcutaneous space with less tissue disruption or injected directly into muscle without a large wound also activated a type 17 response (SFig 3D). There was elevated IgG1 in the blood of mice implanted with PCL compared to saline controls at 6-weeks post-surgery, highlighting B cell response and further supporting engagement of the adaptive immune system (SFig 4A). These results, combined with the clinical data from breast implants, suggest that the TH17 response is activated in response to implants of various size, shape, and texture in different tissue environments.
To determine whether the TH17 response was mediated by the TCR, we used wildtype CD45.1 and OTII-Rag -/-CD45.2 bone marrow chimera mice (Fig 2D) . resolved whereas CD4 + T cells remained and continued to produced IL17 (Fig 2B, SFig 2E ).
This suggests that the IL17 production by CD4 + T cells in response to PCL implantation was antigen specific. As previously described, biomaterials can modulate the T cell response to antigens thereby acting as an adjuvant. Spleenocytes from OTII mice cultured in vitro with OVA in combination with PCL or PE for 48 hours showed increased T cell proliferation compared to without biomaterials.
Chronic IL17 in response to synthetic implants promotes fibrosis
TH17 immune responses are implicated in fibrotic diseases in multiple tissue types including skin, heart, lung, and liver, though have not been studied in the context of FBR [34] [35] [36] [37] . In the wild type (WT) mice that demonstrated a type 17 immune response, the expression of fibrosis related genes after surgery evolved over time (SFig 4D). Without a biomaterial, expression of the extracellular matrix genes collagen I and III initially increased after surgery then decreased by 6 weeks as normal healing progressed and tissue repaired. The presence of the PCL implant significantly increased expression of collagen III and the fibrosis gene S100a4 after 6 and 12 weeks. Masson's trichrome and immunohistochemistry confirmed increased collagenous extracellular matrix and alpha smooth muscle actin protein (αSMA) surrounding the PCL particles (Fig 3A) , features typical of the FBR and fibrotic capsule formation.
To evaluate if fibrosis associated with the FBR to biomaterials was IL17 dependent, we compared the implant response in Il17a -/-and Il17ra -/-mice with WT mice. We found that expression of fibrosis-related genes S100a4, Tgfβ, collagen I and III significantly decreased in both knockout mice implanted with PCL compared to the WT mice (Fig 3B) . The quantity, composition, and organization of ECM visible around the PCL particles decreased in the knockout animals ( Fig 3A) . αSMA immunofluorescence was absent in Il17 signaling deficient and picrosirius red (PSR) staining significantly shifted. PSR visualized with a polarized lens produces birefringence that is specific for collagen fiber organization; larger collagen fibers are bright orange to red and thinner fibrils are green to yellow [38] . A reduction in collagenous matrix and thinner fibrotic capsules around the PCL particles was confirmed in knockout mice compared to WT mice at 12-weeks post-surgery using image analysis and quantification of collagen thickness and green to red illuminant on PSR images (Fig 3C) . Results from the knockout studies suggest that blocking of IL17 signaling may reduce FBR-associated fibrosis without negatively impacting healing. We therefor sought to determine the therapeutic potential of blocking IL17 on fibrosis. Since IL17A and IL17F were both produced in response to the implant and the IL17RA -/-mice showed the greatest reduction in fibrosis compared to IL17A
-/-, we evaluated delivery of IL17A and IL17F specific neutralizing antibodies (IL17A/F NAbs) to test the impact of functional neutralization of IL17R signaling on fibrosis. Mice were treated with IL17A/F NAbs 4 weeks after biomaterial implantation every other day for one week for a total of 5 injections. One week after the IL17A/F NAb treatment, IL17 and IL6 expression decreased. Expression of fibrosis-associated genes Tgfβ and Collagen I also decreased (Fig 3D) . Immunofluorescence of αSMA also decreased, further suggesting reduced fibrosis. Histologically, collagen density and fiber organization decreased with anti-IL17A/F treatment compared to isotype controls (Fig 3C) . PSR staining and quantification demonstrated that IL17A/F NAbs modulated ECM organization and reduced fibrosis to levels that were similar to the knockout animals.
p16 INK4a senescent cells develop during the FBR and senolysis reduces fibrosis
IL6 is a critical mediator contributing to the differentiation of TH17 cells. Since IL6 is associated with the SASP produced by senescent cells, we investigated whether SnCs were a potential source of IL6 contributing to the chronic IL17 production and fibrosis [18] . SnCs are characterized by expression of p16 INK4a , p21 and SASP factors [39] [40] [41] . Consistent with the kinetics of fibrosis development, p16 INK4a expression increased significantly from 6 to 12 weeks after PCL implantation compared to saline controls (Fig 4A) . p16 INK4a positive cells were localized to the peri-implant region and exhibited a fibroblastic morphology with a single nucleus (Fig 4B, SFig 7A ). Fibroblasts sorted from PCL implants expressed significantly higher levels of p16 INK4a compared with healthy and saline controls, whereas sorted macrophages did not express p16 INK4a (SFig 6B, 7B). All materials tested induced p16 INK4a expression to varying levels, again suggesting that the response is material independent (Fig 4D) . SnC development was abrogated in both the IL17A -/-and IL17RA -/-mice at 12 weeks to levels of the no implant controls, demonstrating that their development depended on IL17 (Fig 4C) .
To further validate and define clinical relevance for the association of SnCs with fibrosis and the FBR, we evaluated patient tissue from breast implant exchanges. Significant numbers of To determine if clearance of SnCs associated with the FBR could reduce fibrosis, we administrated the senolytic agent Navitoclax (Navi, ABT-263) that selectively kills SnCs [25, 42] .
Navi was administered alone and in combination with anti-IL17A/F NAbs 4 weeks after implantation, when p16 INK4a expression significantly increased with biomaterial implantation compared to control (Fig 4A) . One week after treatment (6 weeks after implantation), expression of p16 INK4a significantly decreased confirming senolysis (Fig 4G) . Clearance of the SnCs reduced αSMA immunofluorescence, suggesting reduced fibrosis activity (Fig 4E) . Concomitant with p16 INK4a and αSMA reduction, Il17a, Il6, Tgfβ, S100a4, collagen I and III gene expression decreased after senolytic treatment. These genes decreased even further when the senolytic was co-administered with anti-IL17A/F NAbs (Fig 4G) . Altogether these findings demonstrate that cellular senescence sustains excess fibrosis and links to chronic IL17 and fibrogenesis during the foreign body response.
Discussion
Medical implants derived from synthetic materials suffer to some extent from the FBR that not only impairs implant function and longevity but may also in turn impact the host. There are numerous anecdotal reports of systemic illnesses associated with orthopedic and soft tissue implants most notably the breast implant syndrome [43, 44] . With only local inflammatory components considered relevant to the FBR, direct correlation of implant responses with systemic immune pathologies was difficult to connect. Preclinical and clinical observations noted the presence of T cells with implants but their relevance to the fibrotic inflammatory response was unclear [14, 45] . Here we present evidence of an IL17 inflammatory response and cellular senescence in the FBR to biomaterials and implicate them in the associated fibrotic response.
T cells are increasingly recognized for their role in determining repair pathways after tissue damage. We observed a TH17 response to biomaterials with multiple implant chemistries in numerous anatomical locations. B cells and their antibody production have already been associated with tissue damage and more recently with synthetic materials [46] [47] [48] . For example, a B cell response to synthetic materials was discovered with implantation in the intraperitoneal cavity. Moreover, the response was independent of material chemistry and physical properties [48] . In our studies, we utilized particles of materials in order to fill tissue defects in the murine model. These particulates had different sizes, textures and surface properties and can themselves activate a rapid, inflammasome-mediated innate immune responses [49] . suggesting that they are not inducing fibrosis but a byproduct [48, 52] .
The discovery of senescent cells in the FBR presents a novel mechanism for the sustained type 17 inflammation and fibrosis around implants in addition to a new therapeutic target.
Senolytic compounds are being developed to treat numerous age-related diseases including arthritis, cardiovascular and Alzheimer's disease [53, 54] . Clinical studies testing senolytics in idiopathic pulmonary fibrosis are already showing efficacy and more clinical studies are ongoing [55, 56] appears to be the case in post-traumatic osteoarthritis [57] .
Canonical activation of T cells requires presentation of antigen and costimulatory factors.
The lack of CD4 + T cell response to PCL in the chimeric OTII-Rag -/-T cells confirms that the TH17 implant response is antigen dependent. One explanation of an antigen-specific T cell response to materials that do not contain protein is a low-level chemical derivatization selfprotein by components of the synthetic material, such that they now appear as "non-self". The finding of IgG in response to implantation of a synthetic material supports this hypothesis, since haptenization of proteins is necessary for T cell help for Ig switching in activated hapten-specific B cells [58, 59] . Combinations of a biomaterial with host proteins can activate T cells as in the case of titanium implant debris that creates a metal-protein complex that can elicit cell responses [60] . Addition of an implant in the context of tissue damage may modulate the natural adaptive damage response by modifying self-antigens or impacting antigen presentation. Finally, there is evidence that T cells can specifically respond to non-peptidic repeating structures such as sugars and lipids and thus may recognize repeating polymer structures [61, 62] . Regardless of the antigen or combination of antigens, the type 17 immune response is activated and directing key aspects of the FBR and targeting this pathway has therapeutic benefits for biocompatibility.
Engagement of the adaptive immune system introduces the potential influence of environment factors in the FBR beyond the standard genetic that can modulate adaptive immune responses such as infection, history of antigen exposure, and the microbiome. Future studies will investigate the impact of these immunomodulatory environmental factors on the TH17 and senescence responses to biomaterial implants.
